Romlusevimab
Modify Date: 2025-08-26 20:15:54
Romlusevimab structure
|
Common Name | Romlusevimab | ||
|---|---|---|---|---|
| CAS Number | 2509447-08-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RomlusevimabRomlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1][2]. |
| Name | Romlusevimab |
|---|
| Description | Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Romlusevimab 和 Amubarvimab (HY-P99435) 结合 SARS-CoV-2 刺突蛋白的不同表位[1]。 Romlusevimab 与 Amubarvimab 联合使用时具有累加效应[1] 。 |
| In Vivo | Romlusevimab (10 mg/kg，ip，单次)与 Amubarvimab (HY-P99435) 联合使用可在 SARS-CoV-2 感染小鼠模型中保护动物免受 Omicron 感染[1]。 |
| References |
[1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331. |
| No Any Chemical & Physical Properties |